US 12,357,633 B2
Methods of treating cancer by targeting cold tumors
Ellen Filvaroff, Summit, NJ (US); Brian Fox, Summit, NJ (US); Ida Aronchik, Summit, NJ (US); and Tracy Chow, Summit, NJ (US)
Assigned to Celgene Corporation, Summit, NJ (US)
Appl. No. 17/618,415
Filed by Celgene Corporation, Summit, NJ (US)
PCT Filed Jun. 12, 2020, PCT No. PCT/US2020/037521
§ 371(c)(1), (2) Date Dec. 10, 2021,
PCT Pub. No. WO2020/252331, PCT Pub. Date Dec. 17, 2020.
Claims priority of provisional application 62/861,094, filed on Jun. 13, 2019.
Prior Publication US 2022/0273654 A1, Sep. 1, 2022
Int. Cl. A61K 31/506 (2006.01); A61K 31/365 (2006.01); A61K 31/555 (2006.01); C07K 16/28 (2006.01)
CPC A61K 31/506 (2013.01) [A61K 31/365 (2013.01); A61K 31/555 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01)] 22 Claims
 
1. A method of treating cancer in a subject in need thereof, the method comprising:
(a) identifying a patient having a cancer tumor that is a diagnostic positive cold tumor; and
(b) administering to the patient a composition comprising a therapeutically effective amount of a compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
wherein the diagnostic positive cold tumor exhibits a cold tumor signature as defined by
(a) low or no CD8 T cell infiltration within the tumor; and/or
(b) exhibition of T cell non-inflamed or T cell excluded based on the presence of T cells within the tumor; and/or
(c) the presence of T cells within the tumor is measured or estimated by gene expression levels of T cell markers in bulk RNA profiling data, and
wherein the patient's cancer cells exhibit a decrease in the gene expression of one or more interferon response genes, wherein the decrease in the gene expression is relative to the gene expression of a control gene.